Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis

  • STATUS
    Recruiting
  • participants needed
    125
  • sponsor
    Eli Lilly and Company
Send
Updated on 5 August 2020
See if I qualify
body mass index
osteoarthritis
x-rays
chronic pain
knee pain

Summary

This study is being done to test the safety and efficacy of LY3016859 for the treatment of osteoarthritis pain. This trial is part of the chronic pain master protocol (H0P-MC-CPMP) which is a protocol to accelerate the development of new treatments for chronic pain.

Details
Condition Arthritis, Osteoarthritis, Osteoarthritis
Age 40years - 100years
Treatment Placebo, LY3016859
Clinical Study IdentifierNCT04456686
SponsorEli Lilly and Company
Last Modified on5 August 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

Have a visual analog scale (VAS) pain value 40 and <95 during screening
Have a history of daily pain for at least 12 weeks based on participant report or medical history
Have a value of 30 on the pain catastrophizing scale
Have a body mass index <40 kilograms per meter squared (kg/m) (inclusive)
Are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation
Are willing to discontinue all pain medications for condition under study, except rescue medication permitted per protocol, for the duration of the study
Have presence of index knee pain for >12 weeks at screening
Have an x-ray supporting diagnosis of osteoarthritis according to the American College of Rheumatology with a Kellgren-Lawrence grade 2 to 4 radiographic classification of index knee
Are men, or women able to abide by reproductive and contraceptive requirements

Exclusion Criteria

Have second- or third-degree atrioventricular (AV) heart block or AV dissociation or history of ventricular tachycardia
Have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques)
Have surgery planned during the study for any reason, related or not to the disease state under evaluation
Have, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation
There is an inability to rule out other causative or confounding sources of pain in the primary condition under study
Have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision
Have a substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association)
Have congenital QT prolongation or QT interval corrected for heart rate using Fridericia's formula (QTcF) interval measurement >450 milliseconds (msec) for male participants, >470 msec for female participants, or >480 msec for participants with bundle branch block
Have any clinically important abnormality at screening, as determined by investigator, in physical or neurological examination, vital signs, electrocardiogram (ECG), or clinical laboratory test results that could be detrimental to the participant or could compromise the study
Have a positive human immunodeficiency virus (HIV) test result at screening
Are, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide
Have an intolerance to acetaminophen or paracetamol or any of its excipients
Have a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2 years prior to screening
Are largely or wholly incapacitated and unable to participate fully in all protocol procedures, for example, bedridden or confined to a wheelchair, permitting little or no selfcare
Have presence of surgical hardware or other foreign body in the index knee
Have an unstable index joint (such as a torn anterior cruciate ligament)
Have had a surgical procedure or therapeutic injection in the affected knee within 3 months prior to starting the washout period
Have fibromyalgia, chronic pain syndrome, or other concurrent medical or arthritic conditions that could interfere with the evaluation of the index knee
Have a history of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis, or amyloidosis
Have clinical signs and symptoms of active knee infection or crystal disease of the index knee
Have a history of infection in the index joint
Have a history of arthritis due to crystals (e.g., gout, pseudogout)
Have ipsilateral hip osteoarthritis
Have had an intra-articular injection of hyaluronic acid within 24 weeks of screening
Have an estimated glomerular filtration rate (eGFR) of less than 70 milliliters/minute/1.73m during screening
Have any clinically serious or unstable cardiovascular, musculoskeletal disorder, gastrointestinal, endocrinologic, hematologic, hepatic, metabolic, urologic, pulmonary, dermatologic, immunologic, or ophthalmologic disease within 3 months of baseline
Have received any antibodies against nerve growth factor (NGF), or antibodies against EGFR, or EGFR tyrosine kinase inhibitors
Have a history of allergic reactions to monoclonal antibodies, or clinically significant multiple or severe drug allergies, including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis
Have a history or presence of uncontrolled asthma, eczema, significant atopy, significant hereditary angioedema or common variable immune deficiency
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

body mass index
osteoarthritis
x-rays
chronic pain
knee pain

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.